This section discusses the role of anti-CTLA-4 and anti-PD-1/PD-L1 mAbs, as well as novel immune checkpoints (anti-LAG-3 and anti-TIM-3), in CRC. The gene discussed is LAG3; the disease is colorectal carcinoma.